Predictive Oncology Announces Progress in Ongoing Evaluation of Strategic Alternatives
Tuesday, 3rd December at 7:00 am
PITTSBURGH, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today announced progress in its ongoing evaluation of strategic alternatives, which was announced on November 13, 2024.
As part of this process, the Company is considering a wide range of options with a focus on maximizing shareholder value, including a potential sale of the Company, a sale of one or more assets of the Company, a merger, licensing agreement, or other strategic investment. Since the formal process began, the Company has held, and continues to hold, confidential level discussions with a number of prospective partners, and comprehensive due diligence remains ongoing with several parties.